CLINICAL STUDY

Acute effects of interferon-α administration on testosterone concentrations in healthy men

E P M Corssmit, E Endert, H P Sauerwein and J A Romijn

Department of Endocrinology and Metabolism of Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands and 1Department of Endocrinology and Metabolism, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands

(Correspondence should be addressed to E P M Corssmit, Department of Endocrinology, F4–222, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; Email: E.P.Corssmit@amc.uva.nl)

Abstract

Objective: Recombinant human interferon alpha (rhIFN-α) is used therapeutically in malignant disorders and chronic hepatitis. The present study was assessed to study the effects of rhIFN-α on the hypothalamic–pituitary–testicular (HPT) axis.

Design and methods: We performed a saline-controlled cross-over study in six healthy men, sequentially measuring the serum concentrations of gonadotropins, testosterone, the free androgen index (FAI) and sex hormone-binding globulin (SHBG) after a bolus subcutaneous injection of rhIFN-α.

Results: rhIFN-α induced a sustained decrease of both testosterone (from 19.5 ± 1.88 to a nadir of 5.49 ± 0.51 nmol/l at the end of the study) and F AI (from 98.7 ± 14.7 to a nadir of 32.1 ± 5.3 at the end of the study), whereas concentrations of LH, FSH and SHBG were not different between the two studies.

Conclusions: Our results suggest that rhIFN-α affects the HPT axis at the testicular level, either directly or indirectly, and changes feedback relationships between the pituitary and the testis.

European Journal of Endocrinology 143 371–374

Introduction

Recombinant human interferon alpha (rhIFN-α) is used therapeutically in malignant disorders and chronic hepatitis. Besides the immunoregulatory (1) and antiproliferative effects (2–5), several endocrine changes have been documented after administration of interferon alpha (IFN-α) to animals and humans (6–9). For example, IFN-α has been reported to stimulate cortisol release (8, 9) and to induce a euthyroid sick syndrome in healthy humans (10). In vitro, IFN-α directly inhibits testosterone production by rat testis and ovarian cells (11). In addition, IFN-α inhibits human chorionic gonadotropin (hCG)-stimulated testosterone secretion in cultured porcine Leydig cells (12, 13). The data available on the effects of IFN-α on testosterone production in healthy humans or patients with infectious diseases or cancer are not conclusive: both decreased (12) and unchanged (14, 15) testosterone concentrations following IFN-α were found.

To investigate the acute effects of IFN-α on testosterone production, we performed a saline-controlled cross-over study in six healthy men, sequentially measuring the serum concentrations of gonadotropins, testosterone, the free androgen index (FAI) and sex hormone-binding globulin (SHBG) after a bolus subcutaneous injection of rhIFN-α.

Subjects and methods

Subjects and study design

Eight healthy males (age (mean ± s.e.) 23 ± 1 years; weight 79 ± 4 kg; height 183 ± 3 cm) participated in the study. Medical history, physical examination and routine laboratory investigations were completely normal in all subjects. They did not use any medication and had not experienced a febrile disease in the month prior to the study. The study was approved by the Research Committee and the Medical Ethical Committee of the Academic Medical Center, Amsterdam. Written informed consent was obtained from all subjects prior to their participation.

Each subject was studied twice with an interval of at least 4 weeks. On one occasion, a bolus subcutaneous injection of rhIFN-α2b (5 million units/m²; Schering-Plough BV, Amstelveen, The Netherlands), dissolved in 1 ml isotonic saline was given; on the other occasion an equivalent volume of isotonic saline was administered.
(1000 h; t = 0 h). The order in which recombinant IFN-α and isotonic saline was administered to each subject was determined by balanced assignment. Volunteers were fasted overnight (from 1800 h) until the end of each study period (2200 h).

**Blood sampling and assays**

Venous blood samples were obtained directly before administration of rhIFNα or saline, and 2, 4, 6, 8, 10 and 12 h thereafter. Plasma was stored at −20 °C until analysis. All samples from the same individual were run in the same assay. Luteinizing hormone (LH) was measured by an immunoenzymetric assay (Immulite, DPC, Los Angeles, CA, USA; interassay coefficient of variation 2–5%, intra-assay coefficient of variation 2–3%), follicle-stimulating hormone (FSH) by RIA (Amersham International, Amersham, Bucks, UK; interassay coefficient of variation 3–6%, intra-assay coefficient of variation 2–3%), testosterone by an in-house RIA, without extraction and chromatography and with tritiated testosterone as label (interassay coefficient of variation 5–9%, intra-assay coefficient of variation 3–8%) (16), SHBG by IRMA (Farmos Diagnostica, Turku, Finland; interassay coefficient of variation 3–6%, intra-assay coefficient of variation 2–4%).

**Calculations and statistics**

The free androgen index was calculated by multiplying the ratio of testosterone/SHBG×100.

Data are presented as means ± S.E.M. Differences within experiments (differences compared with t = 0) were tested by analysis of variance and Fisher’s LSD test for multiple comparison, as indicated. Data between experiments (IFN-α and control data) were tested by Wilcoxon’s test. A P value < 0.05 was considered to represent statistical significance.

**Results**

**Clinical features**

The clinical signs and symptoms induced by administration of rhIFN-α have been reported previously (17). Briefly, rhIFN-α provoked a mild to moderate headache, and nausea and vomiting in one subject. In all subjects, a rise in rectal body temperature was registered (maximum temperature after 8 h: 38.4 ± 0.2 °C), preceded by mild to moderate chills. Systolic blood pressure increased (from 125 ± 2 to a maximum of 140 ± 4 mmHg) (P < 0.01), whereas diastolic blood pressure decreased (from 81 ± 2 to a minimum of 66 ± 2 mmHg) (P < 0.001).

**LH and FSH**

There were no differences in basal concentrations of LH and FSH between the control day and the rhIFN-α study day (Fig. 1). All baseline concentrations were within the reference range. Plasma LH and FSH levels were not affected by rhIFN-α compared with saline.

**Testosterone, free androgen index and SHBG**

Preinjection plasma testosterone, FAI and SHBG levels were not different between both study periods (Fig. 2). rhIFN-α induced a marked decrease in serum testosterone and FAI levels, becoming significant after six hours and reaching a nadir after twelve hours (5.49 ± 0.51 nmol/l, \( P < 0.02 \) vs control and 32.1 ± 5.3, \( P < 0.03 \) vs control respectively). SHBG levels were not affected by rhIFN-α.

**Discussion**

This study evaluated the acute effects of rhIFN-α administration on the pituitary–testicular axis in healthy humans. The data show that subcutaneous administration of rhIFN-α to humans induces an acute decrease in both testosterone and FAI without any alterations in plasma levels of LH or FSH, indicating that rhIFN-α affects the hypothalamus–pituitary–testicular (HPT) axis at the testicular level.

The acute effects (<12 h) of IFN-α on testosterone concentrations in healthy subjects have not been documented before. The data available on the effects of
IFN-α in healthy humans or patients with infectious diseases or cancer are not conclusive, which is probably related to differences in study design. Orava et al. reported a decrease in serum testosterone concentration measured daily during daily injections of IFN-α (1.5–3 × 10^6 U) for four to ten days in three healthy men (12). In that study, testosterone concentrations returned to control levels after cessation of treatment (12). Piazza et al. documented unchanged serum free testosterone levels, measured every three months during IFN-α (1 × 10^6 U) therapy thrice weekly for twelve months in patients affected by chronic hepatitis C (14). The same was found by Bareca et al., who reported no change in serum free testosterone and LH concentrations, measured every two months during IFN-α (3 × 10^6 U) thrice weekly for six months (15). Since we found a decrease in testosterone concentrations within twelve hours after one injection of rhIFN-α, which was also found by Orava et al. during short term treatment with rhIFN-α (<10 days) (12), whereas no change was found during chronic administration (6–12 months) of rhIFN-α (14, 15), it is possible that there is a difference between the acute and chronic effects of rhIFN-α, such as has been documented for the effects of rhIFN-α on thyroid hormone concentrations (6, 7, 10). Since in our study no measurements of testosterone concentrations were performed later than 12 h after rhIFN-α administration, no conclusions can be drawn about the duration of the hormone effect.

We did not find any effect of administration of rhIFN-α to humans on concentrations of FSH and LH. However, in ovariectomized cows, recombinant bovine interferon-α decreases plasma concentrations of LH two to six hours after injection (18). This discrepancy might be related to interspecies differences (19). Considering the unchanged LH levels several hours after the injection of rhIFN-α, our results point to an effect of IFN-α at the level of the testis as well as to an altered feedback relationship between the pituitary and the testis, since one would expect gonadotropin concentrations to increase when testosterone concentrations decrease. Our findings are supported by data from in vitro animal studies. For instance, IFN-α inhibits testosterone production by rat testis and ovarian cells (11) and hCG-stimulated testosterone secretion in cultured porcine Leydig cells (13, 19). Interestingly, since IFN-α production increases in response to viral infections, it could be speculated that IFN-α might be a mediator in the decrease in testosterone concentrations during viral orchitis.

It is unclear whether rhIFN-α decreases testosterone concentrations directly or indirectly. Critical illness frequently affects the HPT axis, resulting in decreased plasma concentrations of testosterone (20–22). Concomitant activation of other endocrine pathways may be of importance in the etiology of the altered HPT function in systemic disease. Increased circulating levels of corticosteroids may directly inhibit testicular testosterone production (23). In addition, raised levels of epinephrine have been reported to lower plasma testosterone concentrations in man (24). rhIFN-α increases concentrations of plasma cortisol and epinephrine (17). The rise in cortisol could contribute to the decrease in testosterone concentrations, as maximum concentrations of cortisol were reached after eight hours (17) and the inhibitory effects of cortisol in vitro were apparent after about six hours (23). Infusion of epinephrine into healthy men induces a rapid decrease in testosterone levels (24). Therefore, it is likely that increased levels of cortisol and epinephrine induced by IFN-α are, at least in part, involved in the decrease in testosterone concentrations.

In conclusion, this study demonstrates that rhIFN-α induces an acute decrease in both testosterone and FAI in healthy humans without any alterations in plasma levels of LH, FSH or SHBG, suggesting that rhIFN-α affects the HPT axis at the testicular level.

![Figure 2](image-url)
either directly or indirectly, and that rhIFN-α changes feedback relationships between the pituitary and the testis.

Acknowledgements

The authors gratefully thank the workers of the Laboratory of Endocrinology and Radiochemistry of our Institute.

References